Objectives To examine the mechanism behind ASC-mediated amelioration of CiOA pathology. Methods CiOA was induced by intra-articular collagenase injection. Knee joint sections were stained with haematoxylin/eosin, the PMN-specific antibody NIMP-R14, or CD271 to locate ASCs. Gene expression and protein release of chemokines by IL-1b-or S100A8/A9-stimulated ASCs were assessed with qPCR and Luminex. Migration of MACS-isolated PMNs towards ASC-conditioned medium through Transwell membranes was examined using flow cytometry. ASC-PMN co-cultures were analysed with microscopy and Luminex. Phagocytic capacity of PMNs was measured with fluorescent labelled zymosan particles. Results Intra-articular ASC injection on day 7 of CiOA (when IL-1b and S100A8/A9 levels are highest) strongly attracted particularly PMNs, which clustered around ASCs in the synovium 6 hour after injection. IL-1b-stimulation of ASCs in vitro strongly increased protein expression of PMN-attracting chemokines KC, CXCL5, and CXCL7, whereas S100A8/A9 did not. Migration of PMNs towards conditioned medium of IL1b-stimulated ASCs (IL-1b-CM) was significantly enhanced (two-fold increase) when compared to CM of non-stimulated ASCs (NS-CM). After 6 hour co-culturing ASCs with PMNs, both the number of ASCs clustering with PMNs and clustered PMNs per ASC were significantly increased after IL-1b-stimulation. Interestingly, association of PMNs with ASCs significantly diminished the release of KC protein by ASCs (69% lower after 24 hour), and also strongly reduced the release of S100A8/A9 protein by the PMNs. Finally, phagocytosis of zymosan by PMNs was strongly enhanced after priming with IL-1b-CM. Conclusions Local application of ASCs in inflamed CiOA joints results in attraction and clustering of PMNs with ASCs in the synovium, which is likely mediated by IL-1b-induced up-regulation of chemokine release by ASCs. This results in lowered levels of pro-inflammatory S100A8/A9 and enhanced phagocytic capacity of PMNs, enabling the clearance of debris to cease synovitis and promote tissue repair. 
Introduction Tertiary lymphoid structures (TLS) often develop in target tissues of autoimmune diseases (AID) such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis, and Sjögren's syndrome (SS). These structures consist of aggregates of B and T cells with varying degree of organisation and are proposed to promote the generation of autoreactive effector cells and autoantibody production. Modulation of the S1P 1 receptor inhibits egress of pathogenic lymphocytes from lymphoid organs and reduces their availability in circulation. This has proven to be an effective target for the treatment of AID including MS and is currently being considered for early phase clinical trials in SLE and SS. Objectives To investigate the functional targeting of the S1P 1 receptor in a murine model of SS. Methods Cenerimod, an orally active, selective S1P 1 receptor modulator, was administered either preventively (early in inflammation) or therapeutically (established inflammation) in an inducible model of SS to evaluate the efficacy of cenerimod in vivo. Histology, flow cytometry and qPCR were used to analyse the tissue samples. Results Cenerimod induced disaggregation of the lymphocytic structures and resolution of salivary gland (SG) inflammation with a concomitant decrease in focus score, lymphoid structure size and T/B-cell follicular organisation. Mice treated with cenerimod displayed significantly decreased T (naïve, central memory and effector) and B (including CD138 +plasma cells) lymphocyte infiltration in cannulated SG, relative to vehicle treated mice. Interestingly, the lymphocytes from cenerimod treated mice exhibited significantly reduced proliferation as well as reduction in pro-inflammatory cytokine RNAs such as IL-17, IL-21, and IL-6. Furthermore, the gene expression profile associated with TLS formation (LTa, LTb, TNFa, CXCL13, CCL19) was less pronounced in cenerimod treated samples. The cervical lymph nodes draining the salivary glands showed a slight reduction in T lymphocytes, but no significant defects were observed in structure, organisation and production of lymphoid chemokine/cytokines, suggesting that homeostatic regulation of tertiary and physiological lymphoid organs differentially relies on lymphocyte/stromal cell cross-talk during inflammation. Conclusions Together, these data demonstrate that the S1P 1 receptor modulator cenerimod regulates TLS in mice and might therefore be a potential treatment option in AID with TLS formation such as SS and SLE. The data also unveil differential requirements for the establishment and maintenance of secondary versus tertiary lymphoid structures.
